Whanin Pharmaceutical (016580): the quiet leader in psychiatric drugs — why profit collapsed, and whether the rebound is real

Update 2026-08-08 — Q2 results in: scenario ① clears its threshold

Here we place the numerical thresholds we set when this article was published side by side with the provisional second-quarter results disclosed on 29 July 2026. The original text below is left untouched; only the confirmed figures are added here.

Against operating profit of KRW 7.98bn in the same period a year earlier (H1 2025), that is +116.5%. Revenue also rose from KRW 124.33bn to KRW 142.60bn, or +14.7%. What we identified at publication as the case for profit normalisation has, in effect, been confirmed by the results.

The remaining scenario ② (wider shareholder returns after the ownership succession — a full-year 2026 DPS of at least KRW 350, or the introduction of share cancellation or an interim dividend) will be checked against the March 2027 year-end dividend disclosure. The next update for this stock is the third-quarter results. The status has also been recorded in stock tracking.

📈 Series: Company analysis — a series that takes listed companies apart one at a time. See the full list

※ Prices and market capitalisation as of 2026-07-16. Financial figures are cited from DART filings (consolidated basis) together with their sources.

A large share of the drugs prescribed in Korean psychiatry comes not from the big pharmaceutical groups but from this company. Whanin Pharmaceutical has spent more than forty years digging a single well — central nervous system (CNS) drugs — and states in its own annual report that it held “the number one share of Korea’s psychiatric drug market on 2024 IMS data”. In 2025, 82.8% of revenue came from treatments for psychiatric and neurological disorders.

Yet the company’s recent numbers show two contradictory pictures at once. Annual operating profit slid for five consecutive years, from KRW 31.3bn in 2021 to KRW 13.0bn in 2025. The market leader saw profit fall by more than half even as revenue grew. And then came the first quarter of 2026 — operating profit of KRW 9.38bn. A single quarter earned 72% of the previous full year’s profit. Which is the real story: the collapse, or the rebound?

Market capitalisation is roughly KRW 186.7bn (closing price of KRW 10,040 on 2026-07-16 × 18,600,070 shares). That is 44% of total equity of KRW 424.1bn (Q1 2026, consolidated), a PBR of 0.44x. On top of that came the October 2025 succession of the largest shareholding by gift, a jump in the payout ratio to 40.8%, large disposals of treasury shares and a corporate value-up disclosure — heavy changes on the governance side as well. This article sets up two scenarios — “why did profit collapse, and is the first-quarter rebound real?” and “where do shareholder returns go after the succession?” — and verifies them quarter by quarter, beginning with the August half-year report.

How the money is made — CNS drugs at 82.8%

This is the composition of consolidated revenue of KRW 255.2bn in 2025 (DART, 2025 annual report, “II. Business overview”).

The flagship product Quetapine is a quetiapine formulation used in schizophrenia and bipolar disorder, and Efram is an escitalopram formulation used in depression and anxiety disorders. The defining feature of the CNS drug market is prescription inertia. Neither patients nor doctors switch psychiatric medication easily, and once a prescription settles it tends to continue for a long time. Combined with a rising trend in the number of people treated for mental illness in Korea, revenue grew steadily over five years, from KRW 177.8bn to KRW 255.2bn.

The sales structure is a classic prescription-drug model. According to the annual report, the sales organisation is split into CNS divisions 1 and 2, general hospital divisions 1 and 2, ETC divisions 1 and 2 and a wholesale team, selling through two routes — direct sales to hospitals and sales via wholesalers — and all revenue is on credit, collected within one to six months (70.2% in cash settlement, 29.8% in notes). There is no dependence on a particular customer: the company states explicitly that no single external customer accounts for more than 10% of total revenue. Subsidiaries include Ambro B&P in pharmaceutical R&D and As You in general distribution, but they are small.

Five years of numbers — revenue up, profit down

Source: DART fnlttSinglAcntAll (corp 00166573, annual report 11011, consolidated)

All five lines tell the same story. The top line grew 44% over five years, yet operating profit fell 58% and the margin was cut to a third, from 17.6% to 5.1%. Cash flow came down with profit. If the Whanin Pharmaceutical of 2019–2021 was “the high-margin leader in a niche”, the Whanin Pharmaceutical of 2025 has a profit-and-loss structure closer to “a generics maker selling on thin margins and volume”.

Pressure point ① — cost of sales from 47% to 66%, a five-year erosion

Look in the financial statements for where the profit went, and the answer is cost of sales.

Source: calculated from the consolidated income statement in DART filings

The cost ratio rose in each of five straight years. While revenue grew by KRW 77.4bn, gross profit actually fell from KRW 93.5bn to KRW 87.1bn. For five years the structure has been one in which additional revenue does not turn into profit. It is not that selling, general and administrative expenses ate the profit (wages and welfare costs rose only gently); rather, the margin left on each sale grew thinner.

The precise cause of the rising cost ratio — a larger weight of low-margin lines (merchandise and contract manufacturing), raw material prices, or drug-price cuts — is hard to pin down from disclosures alone. There are clues to work with. Among key raw materials there is some dependence on imported inputs such as naltrexone hydrochloride (6.9% of purchases in 2025), and factory utilisation is high at 81.9%, so idle capacity is not the problem. Tracking this breakdown in the product-level revenue and cost notes of the August half-year report is this article’s first piece of homework.

And then Q1 2026 — a sharp rebound

Quarterly operating profit fell all through 2025: KRW 5.28bn (Q1) → KRW 2.70bn (Q2) → KRW 3.56bn (Q3) → KRW 1.48bn (Q4). By the fourth quarter the run rate had dropped to an annualised KRW 6.0bn. Then came KRW 9.38bn in the first quarter of 2026 — up 77.7% year on year and more than six times the preceding quarter. Revenue of KRW 71.2bn (+18.2% yoy) was also close to a record for a single quarter, and the quarterly operating margin of 13.2% marks a return to the level of full-year 2023 (13.1%), before the margin collapse (provisional disclosure of 2026-04-27; the confirmed figures in the quarterly report of 2026-05-13 match).

One quarter’s numbers are not yet a direction. Two points deserve particular care. First, the drop from KRW 1.48bn in the fourth quarter to KRW 9.38bn in the first is so steep that one-off factors cannot be ruled out (the base effect of temporary fourth-quarter costs, shipments of particular products bunching up, the timing of drug-price or rebate settlements). Second, first-quarter operating cash flow was KRW 0.97bn, far apart from operating profit of KRW 9.38bn. That may be down to an increase in working capital (receivables and inventory), but whether profit comes back as cash has to be checked in the half-year cash flow statement. Whether the “revenue of KRW 280.0bn in 2026” the company set out in its value-up disclosure is the actual run rate can also be gauged from first-half revenue (threshold: KRW 140.0bn).

Pressure point ② — the pipeline: is there preparation beyond generics?

The other side of margin erosion is research and development. R&D spending held at KRW 23.2bn a year (2025, about 9.1% of revenue) even as profit shrank. Most of it is treated as manufacturing overhead, so that burden is also folded into the cost ratio in the income statement. The projects listed in the annual report are centred on CNS.

Source: 2025 annual report, R&D progress section (project names as written by the company)

Added to this are the Taiwanese and Chinese partnerships flagged in the value-up disclosure, and animal medicines with “clinical trials scheduled to begin in 2026” as the new-business axis. None of them, however, is yet at a stage that shows up in the profit and loss. The short-term driver of a profit recovery remains the cost ratio in the core business.

Balance sheet — quiet, thick assets

On a Q1 2026 consolidated basis, total assets were KRW 482.0bn, total liabilities KRW 57.8bn and total equity KRW 424.1bn. With a debt-to-equity ratio of 13.6% and no borrowings visible on the accounts, the financial structure is effectively debt-free. The contents of the assets are heavy too — cash and cash equivalents of KRW 58.4bn, investment property of KRW 31.9bn, financial assets at fair value through other comprehensive income of KRW 44.9bn (end-2025) and property, plant and equipment of KRW 143.4bn. Cash, property and financial assets alone come to around KRW 135.0bn, equal to 72% of the market capitalisation (KRW 186.7bn). Retained earnings have piled up to KRW 368.1bn.

The share price has fallen for five years from its 2021 peak (the KRW 23,000 area), tracking the margin erosion almost exactly. Even after the first-quarter earnings surprise it has stayed around KRW 10,000. In other words, the market is not yet treating one quarter as a trend. For the shares of an asset-heavy company to move, one of two things is ultimately needed — confirmation that profit has turned, or assets beginning to flow to shareholders.

Succession, KRW 38.0bn of treasury share disposals, a 40.8% payout ratio — the signals conflict

In the second half of 2025, as profit was bottoming out, heavyweight disclosures clustered on the governance and shareholder-return side. In chronological order, they look like this.

Source: individual DART filings (20250707000278, 20251030800491, 20251211000435, 20251218000442, 20260323800234)

This is where the readings diverge. Look only at the dividend and the picture is friendly — even in a year when profit halved, the company held the payout at KRW 300 per share, lifting the payout ratio from 15.4% (2023) to 19.6% (2024) to 40.8% (2025). The result is “profit may fall, but the dividend is defended”. Treasury shares, on the other hand, were disposed of rather than cancelled. And on three occasions within a single year: 3.217 million shares, equal to 17.3% of shares outstanding (about KRW 38.0bn at the disclosed prices), went out into the market and off-exchange, and the treasury share ratio fell from 17.9% to 0.6%. The counterparties and substance of the “strategic alliances” entered in the purpose field of the two December filings have not been made concrete in later disclosures — a large-shareholding report from May 2026 contains the next clue, and we will track that part in updates.

A company that had only just completed a succession by gift thus put out signals of “wider returns” — the value-up disclosure and a higher payout ratio — and a signal pointing the other way, large disposals of treasury shares, at the same time. Which of the two is structural will be answered by the 2026 year-end dividend and by any further treasury share policy.

Core scenarios — two propositions checked together

There are two propositions this article will check every quarter. The threshold numbers are set in advance and are not moved after the fact.

Scenario ① — profit normalisation. “Annual operating profit, which sank to KRW 13.0bn in 2025, normalises from the KRW 9.38bn of Q1 2026 onwards.”

• Numerical thresholds: H1 2026 cumulative operating profit of at least KRW 14.0bn (at least KRW 4.6bn in the second quarter alone — a pace that clears a third of 2025’s full-year profit within half a year), and first-half revenue of at least KRW 140.0bn (half the pace of the company’s KRW 280.0bn target)
• Supporting checks: has the half-year cost ratio turned down from 65.9% (full-year 2025), and is operating cash flow moving in the same direction as profit
• Falsification condition: if second-quarter operating profit falls back below KRW 3.0bn, or revenue declines year on year, the first quarter is treated as a one-off
• Data to check: the fair-disclosure of provisional results (filed on 1 August last year), and the half-year report in mid-August (submitted on 13 August last year)

Scenario ② — wider shareholder returns after the succession. “The succession by gift (October 2025), the value-up disclosure and the 40.8% payout ratio are not one-offs but the start of a structural widening of returns.”

• Numerical threshold: a full-year 2026 dividend of at least KRW 350 per share, or the disclosure of a new return tool such as cancellation of treasury shares or the introduction of an interim dividend
• Falsification condition: if the dividend is frozen at KRW 300 and treasury share disposals continue, the “wider returns” proposition is rejected
• Data to check: the dividend decision disclosure (normally in February or March of the following year), treasury share disclosures, and follow-up disclosures on the “strategic alliances”

The bull case

① The size and quality of the first-quarter rebound. Operating profit of KRW 9.38bn is the highest quarterly figure in several years, and with revenue (KRW 71.2bn) and margin (13.2%) rising together it is not a rebound built on cost-cutting alone. At this pace, annual profit returns to the 2021–23 level (around KRW 30.0bn).

② The price is low. A PBR of 0.44x. Against a market capitalisation of KRW 186.7bn there are cash, property and financial assets of around KRW 135.0bn plus retained earnings of KRW 368.1bn. The multiple on annualised Q1 2026 profit is not demanding either. This is a price that reflects no premium at all for the leading position in the market.

③ The defensiveness of the core business. CNS prescription drugs continue to be prescribed regardless of the economic cycle, and prescription inertia means market share does not shift easily. Revenue has risen for five straight years, and there is no dependence on any single customer.

④ Incentives after a completed succession. The value-up disclosure and the higher payout ratio came out together under the new controlling shareholder. For a second-generation owner who has finished the succession, this is the phase in which raising corporate value and dividends is directly in his own interest.

The bear case

① The rise in the cost ratio is a five-year trend. There is as yet no evidence that a cost ratio that climbed from 47.4% to 65.9% was broken in a single quarter. The cause of the first-quarter rebound has not been broken down in disclosures, and given the low base of KRW 1.48bn in the fourth quarter, the possibility of an optical illusion remains.

② The quality of profit is unconfirmed. Q1 2026 operating cash flow was KRW 0.97bn — a tenth of operating profit (KRW 9.38bn). If working capital is the cause it should unwind by the half-year mark; if it does not, the quality of profit has to be questioned.

③ Little hard evidence on shareholder returns. The jump in the payout ratio is also an arithmetic consequence of falling profit. The dividend per share has been KRW 300 for three years running, and treasury shares worth KRW 38.0bn were disposed of within a year without any cancellation. The substance of the “strategic alliances” has not been disclosed either.

④ The inertia of a five-year decline, and liquidity. Thick assets or not, the market has no reason to narrow the discount before the direction of profit is confirmed. The low turnover typical of overlooked small caps also has to be taken into account — this is a stock in which it is hard to buy or sell the quantity you want at the price you want.

What to watch next quarter (August 2026)

The results are reflected in the stock tracking ledger. The initial status on entry is ⚪ (first update pending). The full schedule for this season is set out in the earnings season preview.

Three-line summary

One. This is the leader of Korea’s psychiatric drug market, yet a rising cost ratio eroded its operating margin from 17.6% to 5.1%, and the share price fell for five years by as much. Two. First-quarter 2026 operating profit of KRW 9.38bn (+77.7%) is a sign of a return to pre-collapse margin levels, but because of the gap with cash flow and the low fourth-quarter base it is still evidence from a single quarter — the check comes in August, with second-quarter operating profit of KRW 4.6bn as the threshold. Three. A company that has completed its succession put out a 40.8% payout ratio and a value-up disclosure (signals of wider returns) alongside KRW 38.0bn of treasury share disposals (a signal in the opposite direction) — a 2026 year-end dividend of KRW 350 is the second threshold. Neither threshold will be moved after the fact, and the outcome is recorded as it stands in stock tracking.

Sources and disclosure

Sources for the figures: DART electronic disclosures (annual report, quarterly report, provisional results disclosure, treasury share disposal decisions, change of largest shareholder, corporate value-up plan; corp 00166573) and KRX prices. Prices as of 2026-07-16. Statements about market position follow the company’s own wording in its annual report (citing IMS data). Figures may differ after the time of writing (July 2026).

This article is for information purposes and is not a recommendation to buy or sell any particular stock. It does not deal with target prices or trade timing.

Read alongside: How to read financial statements · How to read the cash flow statement · The traps in PER and PBR · Capital allocation

Update log

• 2026-08-15 — Each company covered here now has its own filing-traceable data page: price-to-book against total equity and against the owners’ share, five years of revenue, profit, equity and net cash, and the dividend, treasury and cancellation record — every figure beside the DART receipt it was read from. → Whanin Pharm (016580)

Related reading

SK Hynix Filed a KRW 40tn Buyback and a Cancellation on the Same Day. That Pairing Is the Whole Point.Bought Back, and Then What? Treasury Stock and Cancellation at 183 Korean CompaniesWhen the Cash Is Heavier Than the Company: Nine Korean Companies at 30%+ Net Cash